(NYSE:NX), NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: […]

(NASDAQ:MDXG), MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16th Annual Alpha Select Conference | New York, NYTuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services

(NASDAQ:CLDX), Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Phase 2 barzolvolimab data in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) demonstrating sustained efficacy

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock GlobeNewswire November 10, 2025 WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced

Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights GlobeNewswire November 10, 2025 Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, Nov. 10, 2025

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire November 10, 2025 Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide Enrollment streamlined across Ntrust-1 and Ntrust-2

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 10, 2025 Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 study, the Company expects

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock GlobeNewswire November 10, 2025 BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of $100 million

Gevo Reports Third Quarter 2025 Financial Results GlobeNewswire November 10, 2025 ENGLEWOOD, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”), a leading developer of cost-effective, renewable hydrocarbon fuels and chemicals that also can deliver significant carbon emission abatement, today announced financial results for the third

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Quanex Building Products Corporation Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – NX GlobeNewswire November 10, 2025 NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex